First author [ref. no.] | Method | QS % | Patients n | p53+ % | HR | 95% CI |
Carbone 20 | PCR-;SSCP | 52 | 85 | 53 | 0.88 | 0.46–1.67 |
Dalquen 22 | IHC | 54 | 215 | 47 | 1.37 | 0.99–1.89 |
Ebina 26 | IHC-;DO-;7 | 55 | 138 | 36 | 3.55 | 1.54–8.22 |
Esposito 27 | IHC-;DO-;7 | 53 | 61 | 36 | 2.15 | 1.06–4.38 |
Fontanini 29 | IHC-;1801 | 57 | 48 | 48 | 2.63 | 1.29–5.38 |
Fontanini 30 | IHC-;1801 | 52 | 107 | 50 | 2.02 | 1.07–3.82 |
Fujino 32 | IHC-;DO-;7 | 70 | 63 | 57 | 1.80 | 0.99–3.25 |
Geradts 34 | IHC-;DO-;7 | 52 | 103 | 49 | 0.83 | 0.49–1.42 |
Horio 42 | PCR-;SSCP | 52 | 71 | 49 | 2.45 | 1.32–4.55 |
Ishida 45 | IHC-;DO-;7 | 72 | 114 | 39 | 2.30 | 0.56–9.19 |
Kim 10 | IHC | 79 | 62 | NC | 0.90 | 0.30–2.70 |
Laudanski 56 | IHC-;DO-;7 | 78 | 84 | 55 | 2.69 | 1.31–5.52 |
Lavezzi 57 | IHC–1801 | 52 | 152 | 16 | 1.25 | 0.69–2.26 |
Lee 58 | IHC-;DO-;7 | 63 | 156 | 65 | 1.06 | 0.61–1.84 |
Moldvay 68 | IHC | 45 | 83 | 55 | 2.54 | 1.22–5.29 |
Morkve 69 | IHC-;1801 | 57 | 112 | 77 | 1.41 | 0.74–2.70 |
Nishio 71 | IHC-;DO-;7 | 63 | 208 | 46 | 1.08 | 0.73–1.60 |
Top 88 | PCR-;DGGE | 46 | 46 | 67 | 2.51 | 0.96–6.56 |
Tormämen 89 | IHC | 49 | 71 | 52 | 2.41 | 1.40–4.16 |
Vega 90 | PCR-;SSCP | 63 | 62 | 26 | 3.02 | 1.05–8.68 |
Overall | ||||||
Fixed-effects model | 54 | 2041 | 48 | 1.56 | 1.37–1.79 | |
Random-effects model | 1.66 | 1.37–2.01 |
QS: quality score
p53+: presence of an abnormality of p53
HR: hazard ratio
CI: confidence interval
PCR: polymerase chain reaction
SSCP: single-strand conformation polymorphism method
IHC: immunohistochemistry with antibodies other than DO-;7 or 1801
IHC-;DO-;7: immunohistochemistry with monoclonal antibody DO-;7
IHC-;1801: immunohistochemistry with monoclonal antibody 1801
DGGE: denaturing gradient gel electrophoresis
For group of NSCLC, surgically resected n=20
Chi-;squared statistic for heterogeneity = 33.82, 19 degrees of freedom, p=0.02